Computer-Animated Character for Understanding Medical Illustrations
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how well people understand medical illustrations with the assistance of a computer-animated character, known as an Embodied Conversational Agent (ECA). The study tests whether viewing this character on a regular computer screen or in virtual reality improves understanding and reduces anxiety compared to reading independently. It suits individuals who speak English or Spanish fluently and have adequate vision to read educational materials. Participants will either use a computer-animated guide in 2D or 3D or read without digital assistance. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could enhance patient education and reduce anxiety.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this computer-animated character is safe for understanding medical illustrations?
Research has shown that using animated helpers on computer screens, known as 2D embodied conversational agents (ECAs), is generally safe. Studies have found no major safety concerns when these agents discuss health topics. Similarly, researchers have examined 3D ECAs, used in virtual reality, for their role in training and health education, with no significant safety issues reported. Both types of ECAs help people understand and engage with health information, indicating they are well-tolerated and safe for use in studies like this one.12345
Why are researchers excited about this trial?
Researchers are excited about the use of Embodied Conversational Agents (ECAs) because they could transform how patients understand medical information. Unlike traditional methods, which rely on static text and images, ECAs provide interactive, personalized explanations, making complex medical concepts easier to grasp. The trial explores two unique formats: a 2D version on a computer monitor and an immersive 3D experience in virtual reality. These innovative approaches aim to enhance patient comprehension and engagement, potentially leading to better health outcomes.
What evidence suggests that the Embodied Conversational Agent is effective for understanding medical illustrations?
Studies have shown that digital assistants, known as Embodied Conversational Agents (ECAs), greatly enhance how people understand and engage with healthcare information. Research indicates that ECAs help people learn more and even improve their quality of life. These digital assistants excel at explaining complex information in an easy-to-understand manner by offering interactive and personalized explanations. In this trial, participants will experience either a 2D or 3D version of these assistants, both of which have increased user interest and serve as useful tools for explaining medical images. Although specific data on reducing anxiety is limited, the engaging nature of ECAs suggests they might help by making information easier to grasp.12367
Who Is on the Research Team?
Timothy Bickmore, PhD
Principal Investigator
Northeastern University
Are You a Good Fit for This Trial?
This trial is for adults over 18 who speak English or Spanish fluently, can consent on their own, and have good enough vision (with glasses if needed) to read educational documents. There are no specific exclusion criteria listed.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage with patient education documents using different methods: unaided, with a 2D ECA, or with a 3D ECA in virtual reality
Follow-up
Participants are assessed for knowledge, anxiety, satisfaction, reading effort, and acceptability after the session
What Are the Treatments Tested in This Trial?
Interventions
- Embodied Conversational Agent (ECA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northeastern University
Lead Sponsor
Boston University
Collaborator
Tufts Medical Center
Collaborator